Outcome of Board meeting inter alia for considering and approving Unaudited Financial Results for Quarter-1 of F.Y. 2026-27, ended on June 30, 2026.

Filed: 14 Aug 2026, 18:33 IST Exchange: BSE Category: Financial Results — Audited Results

Q1FY27 results (unaudited): Standalone: Revenue 3.0bn +16% y-y (2.6bn) PAT 0.12bn n.m. y-y (-0.24bn) Consolidated: Revenue 3.0bn +16% y-y (2.6bn) PAT 0.03bn n.m. y-y (-0.57bn) FY26 results (audited): Standalone: Revenue 12.3bn n.a. (no prior year data in filing) PAT 0.35bn n.a. Consolidated: Revenue 12.3bn n.a. PAT 0.10bn n.a. Commentary: The quarter and year results reflect the impact of the amalgamation of Dhanuka Laboratories Limited effective April 1, 2024, accounted from the appointed date. Exceptional items relate to incremental estimated liabilities for past service cost due to new Labour Codes.

Source: Original filing PDF — view on exchange portal

⚡ You're reading this after the fact — subscribers got it instantly

ISA

Indian Stock Alerts BOT

🚨 ORCHPHARMA — Quarterly Results

Revenue: ₹2,35,800 Cr (+12% YoY)

PAT: ₹19,200 Cr (+17% YoY)

EBITDA margin: 16.8%

Board declared ₹10/share dividend. Jio adds 8M subs.

📎 bseindia.com/xml-data/...

🎧 Audio summary ready

✓✓ 6:47 PM

🎧

Instant audio summaries2-min AI concall recap delivered with every earnings alert

📊

20-quarter financialsRevenue, PAT, EBITDA, margins — auto-extracted from filings

🔍

Forensic red-flag screenAudit, governance, accruals & RPT flags scored automatically

⚡

Instant Telegram alertsResults, board meetings, insider trades — within minutes

Add ORCHPHARMA to your watchlist — all of this, automated.

14-day Pro trial · No credit card · Cancel anytime

More on Orchid Pharma Limited

Important. The summary above is generated automatically from Orchid Pharma Limited's own public regulatory filing under SEBI LODR. Indian Stock Alerts is not a SEBI-registered Research Analyst or Investment Adviser. This page is informational, not investment advice, a recommendation to buy or sell any security, or any opinion about the company's business, governance or financial health. Always read the original filing before acting and consult a registered adviser for investment decisions.